18F-LY3950321-01 Biodistribution and Safety Study

Radiation Exposure Clinical Trial

Official title:

A Phase 1, Open-label Study to Evaluate the Biodistribution and Safety of 18F-LY3950321 (18F-MNI-1256) in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05775601
• Other study ID #: 18F-LY3950321-01
• Status: Completed
• Phase: Early Phase 1
• Start date: February 28, 2023
• Est. completion date: April 4, 2023

Study information

• Verified date: April 2023
• Source: Avid Radiopharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

18F-LY3950321 (also known as 18F-MNI-1256) is a radiolabeled positron emission tomography (PET) tracer targeting granzyme B. The overall goal of this protocol is to evaluate the safety, tolerability, and radiation dosimetry of 18F-LY3950321.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: April 4, 2023
• Est. primary completion date: April 4, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy with no clinically relevant finding on physical examination at Screening and upon reporting to the clinic for the Imaging Visit.

• Female subjects must not be of childbearing potential, or if they are of childbearing potential to agree to use contraception and not donate eggs.

• Male subjects with their partners of childbearing potential must commit to the use of 2 methods of contraception, 1 of which is a barrier method for male subjects for the study duration and 90 days after study completion.

• Male subjects must not donate sperm for the study duration and for 90 days after study completion.

Exclusion Criteria:

• Current or prior history of any alcohol or drug abuse in the past 2 years.

• Currently exposed to nicotine products or had regular nicotine exposure within a six-month period, to be verified by urine cotinine screening.

• ECG or Laboratory tests with clinically significant abnormalities and/or clinically significant unstable medical illness.

• Known history of hypersensitivity, including hypersensitivity to the active substances used for 18F-LY3950321 or derivatives, or to any of the associated excipients.

• Subject has received an investigational drug within 30 days or five half-lives prior to Day 1, whichever is longer.

• Prior participation in other research protocols or clinical care during the past year that would result in radiation exposure to an effective radiation dose exceeding the acceptable annual limit established by the US Federal Guidelines (effective dose of 50 milliSieverts, including the procedures in this clinical protocol).

• Pregnant, lactating or breastfeeding.

• Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease.

• Unsuitable veins for repeated venipuncture.

• Use of any prescription drugs (except approved forms of birth control) or herbal supplements, within 4 weeks prior to Day 1.

• Use of any over-the-counter (OTC) medication or dietary supplements (vitamins included) within 2 weeks prior to Day 1.

• Subject is, in the opinion of the Investigator, unsuitable in any other way to participate in this study.

Related Conditions & MeSH terms

• Radiation Exposure

Intervention

Drug:
• 18F-LY3950321
3 millicuries (±1 mCi)

Procedure:
• PET Scan
positron emission tomography (PET) scan

Locations

Country	Name	City	State
United States	Invicro, LLC	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Avid Radiopharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (3)

Harrison J, Lopez PO. Use of effective dose in medicine. Ann ICRP. 2015 Jun;44(1 Suppl):221-8. doi: 10.1177/0146645315576096. Epub 2015 Mar 25. — View Citation

International Commission on Radiological Protection. Human alimentary tract model for radiological protection. ICRP Publication 100. A report of The International Commission on Radiological Protection. Ann ICRP. 2006;36(1-2):25-327, iii. doi: 10.1016/j.icrp.2006.03.004. — View Citation

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005 Jun;46(6):1023-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	18F-LY3950321 Whole Body Effective Dose	Radiation dose estimates. Distribution data will be utilized in the MIRD calculations of target organ radiation absorbed dose with correction from urine assays and standard GI kinetic models in Organ Level Internal Dose Assessment (OLINDA). Standard Medical Internal Radiation Dose (MIRD) assumptions will be incorporated in dosimetry models for determination of radiation absorbed doses in target organs and whole-body.	injection to 4 hours postdose